EyePoint (EYPT) Net Income (2010 - 2026)
EyePoint (EYPT) posted Net Income of -$120.2 million for Q1 2026, down 77.79% sequentially from -$67.6 million in Q4 2025, and down 129.33% YoY from $409.9 million in Q1 2025.
Analysis
EyePoint (EYPT) Net Income (2010 - 2026) Analysis & Trends
EyePoint has reported Net Income for 17 years, with the latest figure at -$120.2 million in Q1 2026.
- Quarterly Net Income fell 129.33% year-over-year to -$120.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$307.0 million (down 99.33% YoY) and the FY2025 annual result came in at -$232.0 million, down 77.25% from the prior year.
- Net Income fell to -$120.2 million in Q1 2026 per EYPT's latest filing, from -$67.6 million in the prior quarter.
- Over five years, Net Income peaked at -$17.0 million in Q4 2023 and troughed at -$120.2 million in Q1 2026.
- A 5-year average of -$53.2 million and a median of -$44.3 million in 2022 frame the typical range for Net Income.
- The sharpest annual moves came in 2022 and 2023: Net Income sank 643.39% in 2022, then soared 72.55% in 2023.
- Over 5 years, Net Income stood at -$44.3 million in 2022, then soared by 61.67% to -$17.0 million in 2023, then slumped by 143.84% to -$41.4 million in 2024, then tumbled by 63.31% to -$67.6 million in 2025, then slumped by 77.79% to -$120.2 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$120.2 million, -$67.6 million, and -$59.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 | -94.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -94.47 Mn |
| Mar 31, 2026 | -87.34 Mn |
| Dec 31, 2025 | -67.71 Mn |
| Sep 30, 2025 | -59.73 Mn |
| Jun 30, 2025 | -59.43 Mn |
| Mar 31, 2025 | -48.94 Mn |
| Dec 31, 2024 | -41.50 Mn |
| Sep 30, 2024 | -29.36 Mn |
| Jun 30, 2024 | -30.83 Mn |
| Mar 31, 2024 | -33.35 Mn |
| Dec 31, 2023 | -16.33 Mn |
| Sep 30, 2023 | -14.40 Mn |
| Jun 30, 2023 | -23.20 Mn |
| Mar 31, 2023 | -22.31 Mn |
| Dec 31, 2022 | -44.38 Mn |
| Sep 30, 2022 | -19.01 Mn |
| Jun 30, 2022 | -19.95 Mn |
| Mar 31, 2022 | -19.53 Mn |
| Dec 31, 2021 | -19.44 Mn |
| Sep 30, 2021 | -16.70 Mn |